Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ALXN2030 in adult kidney transplant recipients with antibody-mediated rejection
CTR20253907Phase 2Active
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in humoral rejection comparing ALXN2030 with Placebo (2 arms). Primary endpoint: Biopsy-confirmed histologic remission. Started Mar 2026; status: active.
02
Drugs
ALXN2030
03
Conditions
humoral rejection
Beyond the preview
Go deeper on CTR20253907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253907.